Apollomics, Inc., a biotechnology company, engages in the discovery and development of mono and combination oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. Its pipeline consists of various development-stage assets, including novel and humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. Apollomics, Inc. was incorporated in 2016 and is based in Foster City, California with additional locations in Hangzhou and Shanghai, China and Southbank, Australia.
Часто задаваемые вопросы
В каком секторе работает Apollomics Inc. Warrant (APLMW)?
Apollomics Inc. Warrant относится к сектору Здравоохранение.
Какова текущая цена акций Apollomics Inc. Warrant (APLMW)?
По последним данным, цена акций Apollomics Inc. Warrant составляет 0,01 $, предыдущее закрытие — 0,01 $.
Выплачивает ли Apollomics Inc. Warrant (APLMW) дивиденды?
Нет, Apollomics Inc. Warrant не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Apollomics Inc. Warrant (APLMW)?
У компании Apollomics Inc. Warrant бета 0.847, что означает, что её волатильность примерно соответствует рыночной.
